back to overview

SFDR – How does MTIP approach the EU’s Sustainable Disclosure Regulation?

April 13, 2021 + Jessica Di Palo
3 Min read

SFDR European regulation

The Sustainable Finance Disclosure Regulation (SFDR) was issued by the European Commission and came into effect on 10 March 2021. The aim of this legislative is to steer European capital towards more sustainable investments by putting in place disclosure requirements regarding sustainability objectives, risks and impacts.

These disclosure requirements will change the way managers all over the world advise and communicate on sustainable investments going forward. At MTIP, a Switzerland-based private equity fund, we are proud to be one of the first managers to comply with this new EU regulation and have achieved the dark green status.

What did MTIP do to integrate the SFDR measures?

As long-term investors in digital health innovation, we understand that value creation and social responsibility go hand-in-hand: both are critical for creating successful and sustainable businesses that improve lives. By focusing on investments in the digital health sector, we aim to enhance the lives of millions of people over the coming decade and beyond. We are committed to identifying and addressing material ESG issues during all phases of the investment process, and have published all required sustainability contents on our website.

Our Investment Manager, Danchen Zhao CFA, CAIA, led the implementation of the Sustainable Disclosure Regulation at MTIP. In the interview below, she tells us about our investment approach and the new SFDR regulation. Read her interview below.

JD (Jessica Di Palo): Danchen, could you please explain to our readers, how we do approach investing at MTIP?

DZ (Danchen Zhao): “Of course, let me start with this: at MTIP we harness the power of specialization. We focus on investing in healthtech, supporting promising solutions that improve access to quality healthcare. Our focus gives us unrivaled absorptive capacity, enabling us to quickly recognize the value of promising healthtech solutions and optimally support the selected founders in commercial scaling. The more they scale with our help, the bigger our impact on the quality and accessibility of healthcare.”


Danchen Zhao, CFA, CAIA Portrait

JD: Everybody is talking about ESG now. At MTIP we are following this investment approach already for many years. How do we integrate ESG into our investment process exactly?

DZ: “ESG integration can be seen in our screening, monitoring and engagement. We screen investment opportunities based on product, team, business model, financials and ESG criteria. For each portfolio company, we establish with the management team a set of operational, financial and ESG KPIs that will be included in their quarterly reports. When we notice a lack of progress on a defined KPI, which could be an ESG KPI, we engage with their management team to find the best way forward.”

JD: This sounds very promising. And to conclude, what are the biggest opportunities for companies in terms of ESG in your opinion?

DZ: “Most companies we work with want to attract talent, sign big clients, raise more money, and potentially get listed in an IPO. Good ESG performance offers opportunities to be successful on all four fronts. The brightest minds of today want to work for companies that contribute to the society and have a positive impact on the world. The biggest potential clients are multinationals that need to maintain their positive brand image and prefer to work with partners that share their values. An increasing number of our fellow investors are looking at ESG and impact of companies when doing their due diligence for a potential participation in a financing round. And any of the major consulting firms will tell you the importance of ESG matters in IPO communications. We are well equipped to support promising healthtech businesses in all aspects.”


MTIP is now one of the first Funds to have achieved the dark green status. We will tell you more about the different statuses in another Blogpost.

Share the Article


Dealroom Report: Tooling the Physicians of the Future

European startups addressing clinical capacity bottlenecks


MTIP Office Featured in Swiss Office Blog

MTIP Office Featured in Swiss Office Blog


Diversity, Equity, and Inclusion: The 3 Key Drivers for Success

We have talked with Caroline Noublanche, CEO of our portfolio company Apricity, about her company’s DEI efforts.


Growth Capital Decisions – An Interview with our Co-Founder & Managing Partner Dr. Christoph Kausch

Growth Capital Decisions


Rahel Hafner Receives Certificate in ESG Investing by CFA Institute

Rahel Hafner Receives Certificate in ESG Investing


What Makes a Great Founder/Investor Relationship?

Interview with the CEO and Co-Founder Kai Eberhardt of our portfolio company Oviva


MTIP’s HealthCare Clinic 2022

This year's HealthCare Clinic was held under the motto: "Surfing the Healthtech Waves of Change".


Christoph Kausch selected by Real Deals as most influential for 2022

Christoph Kausch named by Real Deals most influential for 2022


MTIP leads €17 million financing round in virtual fertility clinic Apricity

New MTIP investment


MTIP leads the €20 million growth financing round in LynxCare

Largest capital round ever in digital health in Belgium


Pioneering the use of machine learning algorithms to turbo-charge drug development

Intelligencia revolutionizes drug development


The psychology of decision making

What makes a good investor?


Revolutionizing medical triage with artificial intelligence

Mediktor's solution for medical triage


MTIP Closes Second Healthtech Growth Fund Above Target With $250M of Commitments

MTIP Fund II is closed!


Cynerio Now! – A new IoT cybersecurity solution for small hospitals and clinics

Cynerio's new product Cynerio Now!


MTIP invests in Mediktor

New investment in Mediktor


SFDR Art. 8 or Art. 9? What’s the difference?

SFDR: getting the terminology right


MTIP participates in Oviva’s new $80m Series C funding

Oviva raises $80 million financing round


MTIP invests in Intelligencia to reduce the risk of clinical research through artificial intelligence

MTIP's new investment in Intelligencia


Private Equity 101: Part one – Glossary

Are you new to the healthtech space?


Leading brands revolutionize care journeys with Lumeon

How Lumeon orchestrates care journey


Trialbee – our hero in patient matching and recruiting for clinical trials

Trialbee - patient matching and recruiting

news blog

Digital healthcare: patient-first?

Digital Healthcare Report 2021 in collaboration with Dealroom and INKEF Capital

SFDR – How does MTIP approach the EU’s Sustainable Disclosure Regulation?

New SFDR obligations


MTIP Announces Strong First Closing of Fund II to drive Healthtech Innovation

First Closing of Fund II